HIV treatment study for people starting therapy
Treatments studied
Part of Hormones & metabolism, Immune system & allergy, Infections clinical trials.
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have HIV.
- You have never taken any HIV medications before.
- Your viral load is between 500 and 500,000 copies/mL.
- You have not used PrEP or PEP in the past.
- Your kidney function is at least 30 mL/min (adequate).
- You are a beneficiary of the Mexican Social Security Institute (IMSS) treated at Hospital de Enfermedades Infecciosas, La Raza National Medical Center.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a three-drug regimen (darunavir/cobicistat plus tenofovir alafenamide/emtricitabine) in men whose HIV is already suppressed. The goal is to find a simpler, effective option that may have fewer side effects.
This study tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug regimen in men whose HIV is already well-controlled. If effective, this could mean taking fewer medications.
This study tests a newer HIV medication, B/F/TAF, as a first-line treatment. It compares B/F/TAF with older combinations (TDF+3TC+EFV or DTG/3TC) to see how well it works for people who have never taken HIV meds.
This trial compares two different daily pill combinations for people newly starting HIV treatment who are overweight or have obesity. It aims to see which one works better for controlling the virus and managing weight.
This study tests whether switching your HIV medication to a combination called DOR/3TC/TDF can help with weight changes that started after taking another type of HIV drug (integrase inhibitor). It is for people who have gained weight unintentionally and want to see if a different medication helps manage it.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
Hear when a new Metabolic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.